You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma

Article info

Article menu

Download PDFPDF

XML
Immunotherapy biomarkers
Original research
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma

Authors

  • Niklas Klümper Department of Urology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Damian J Ralser Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany Department of Obstetrics and Gynecology, University Hospital of Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Emma Grace Bawden Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Jenny Landsberg Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany Department of Dermatology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Romina Zarbl Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Glen Kristiansen Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany Institute of Pathology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Marieta Toma Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany Institute of Pathology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Manuel Ritter Department of Urology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Michael Hölzel Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Jörg Ellinger Department of Urology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Dimo Dietrich Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, University Hospital Bonn, Bonn, Germany Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles

Citation

Klümper N, Ralser DJ, Bawden EG, et al
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
Journal for ImmunoTherapy of Cancer 2020;8:e000552. doi: 10.1136/jitc-2020-000552
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.